Hepatocellular Carcinoma: Therapeutic Strategy in 2017

被引:1
|
作者
Diaz-Gonzalez, A. [1 ,2 ]
Forner, A. [1 ,2 ]
机构
[1] Hosp Clin Barcelona, IDIBAPS, CIBEREHD, Liver Unit,Barcelona Clin Liver Canc BCLC Grp, C Villarroel 170,Escala 11,4a Planta, E-08036 Barcelona, Spain
[2] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona, Spain
关键词
Tumor staging; Prognosis; BCLC; Therapy; RANDOMIZED CONTROLLED-TRIAL; DOXORUBICIN-ELUTING BEADS; TRANSARTERIAL CHEMOEMBOLIZATION; DOUBLE-BLIND; PORTAL-HYPERTENSION; 2ND-LINE TREATMENT; PHASE-3; TRIAL; SORAFENIB; PLACEBO; SURVIVAL;
D O I
10.1007/s10269-017-2713-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hepatocellular carcinoma (HCC) is the most frequent primary neoplasm of the liver and it is the most relevant cause of death among patients with chronic liver disease. Prognosis assessment is a critical step in the management of HCC patients. Any attempt to assess the prognosis should consider not only information regarding tumor stage but also data about the degree of liver function impairment and the presence of cancer-related symptoms. In addition, any system aimed to be clinically successful should optimally attempt to link prognostic prediction and treatment indication. The Barcelona Clinic Liver Cancer staging system is the most accepted staging system. It has been externally validated, takes into account the most relevant prognostic parameters, and suggests the treatment approach based on the best scientific evidence. This article summarizes the most updated treatment strategy of HCC and future perspectives.
引用
收藏
页码:177 / 183
页数:7
相关论文
共 50 条
  • [1] THERAPEUTIC STRATEGY OF HEPATOCELLULAR CARCINOMA BY LAPAROSCOPIC HEPATECTOMY
    Kaneko, Hironori
    Otsuka, Yuichiro
    [J]. ANTICANCER RESEARCH, 2014, 34 (10) : 5985 - 5986
  • [2] Synthetic lethality: A promising therapeutic strategy for hepatocellular carcinoma
    Tang, Linsong
    Chen, Ronggao
    Xu, Xiao
    [J]. CANCER LETTERS, 2020, 476 : 120 - 128
  • [3] Exosomal microRNAs as a potential therapeutic strategy in hepatocellular carcinoma
    Angélique Gougelet
    [J]. World Journal of Hepatology, 2018, (11) : 785 - 789
  • [4] Exosomal microRNAs as a potential therapeutic strategy in hepatocellular carcinoma
    Gougelet, Angelique
    [J]. WORLD JOURNAL OF HEPATOLOGY, 2018, 10 (11) : 785 - 789
  • [5] Lenvatinib applicability in the therapeutic strategy of patients with hepatocellular carcinoma
    Merle, Philippe
    [J]. HEPATOBILIARY SURGERY AND NUTRITION, 2023, 12 (02) : 248 - 251
  • [6] The appropriate place of radiotherapy in the therapeutic strategy for hepatocellular carcinoma
    Girard, N.
    Mornex, F.
    Trepo, C.
    Merle, P.
    [J]. ONCOLOGIE, 2007, 9 (06) : 482 - 486
  • [7] Adenoviral transduction of TRAIL as a therapeutic strategy for hepatocellular carcinoma
    Bitzer, M
    Armeanu, S
    Gregor, M
    Lauer, UM
    [J]. GASTROENTEROLOGY, 2002, 122 (04) : A651 - A651
  • [8] Oncogenic signal transduction and therapeutic strategy for hepatocellular carcinoma
    Tanaka, S
    Sugimachi, K
    Maehara, S
    Harimoto, N
    Shirabe, K
    Wands, JR
    Sugimachi, K
    [J]. SURGERY, 2002, 131 (01) : S142 - S147
  • [9] A new therapeutic strategy for hepatocellular carcinoma to suppress angiogenesis.
    Ishii, Y
    Inagaki, Y
    Ogawa, R
    Aoki, T
    [J]. GASTROENTEROLOGY, 1999, 116 (04) : A1224 - A1224
  • [10] Multi-target siRNA: Therapeutic Strategy for Hepatocellular Carcinoma
    Li, Tiejun
    Xue, Yuwen
    Wang, Guilan
    Gu, Tingting
    Li, Yunlong
    Zhu, York Yuanyuan
    Chen, Li
    [J]. JOURNAL OF CANCER, 2016, 7 (10): : 1317 - 1327